NP / PA
Munson Healthcare Manistee Hospital
Munson Healthcare Manistee Hospital was paid $9.52M by Medicaid between Jan 2018 and Dec 2024, across 225 billing codes. Its largest line is 41899, Unlisted procedure, dentoalveolar structures — 22% of everything it billed.
33Billing provider infoMUNSON HEALTHCARE MANISTEE HOSPITAL
MANISTEE, MI 49660
MANISTEE, MI 49660
33aNPI1407949191assigned 10/02/2006
33bProvider typeCertified Registered Nurse Anesthetist
28Total paid$9.52M
24GClaims304,476
24DCodes billed225
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Certified Registered Nurse Anesthetist providers in Michigan
Rank by total paid#1 of 80
Median peer was paid$87K
This provider vs. median109×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,711 | $1.14M | |
| 2019 | 38,977 | $988K | |
| 2020 | 36,079 | $862K | |
| 2021 | 51,015 | $1.31M | |
| 2022 | 53,763 | $1.54M | |
| 2023 | 46,410 | $1.98M | |
| 2024incomplete | 35,521 | $1.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 41899 | Unlisted procedure, dentoalveolar structures | 22% | 1,532 | 1,524 | $2.06M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 9,242 | 8,457 | $1.65M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 8,450 | 8,119 | $1.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.6% | 2,965 | 2,799 | $917K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.1% | 5,137 | 4,690 | $490K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.6% | 4,879 | 4,708 | $338K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 1,494 | 1,451 | $245K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.4% | 4,431 | 3,950 | $225K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 8,203 | 2,642 | $165K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.7% | 4,096 | 3,785 | $159K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 3,665 | 3,517 | $135K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 4,122 | 3,602 | $131K |
213 more codes
| 99204 | Doctor's office visit, new patient (more involved) | 1.3% | 1,457 | $123K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 2,572 | $114K |
| 99203 | Doctor's office visit, new patient (routine) | 1.1% | 1,822 | $103K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,569 | $76K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 840 | $68K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,442 | $67K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 857 | $66K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,477 | $60K |
| 80061 | Lipid panel | <1% | 6,017 | $57K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,156 | $57K |
| 80053 | Comprehensive metabolic panel | <1% | 19,559 | $54K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,984 | $44K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,108 | $41K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,686 | $39K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,214 | $36K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 875 | $34K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 560 | $32K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 411 | $31K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 285 | $30K |
| 59025 | Fetal non-stress test | <1% | 607 | $30K |
| 82947 | <1% | 2,799 | $29K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 423 | $28K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,622 | $28K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,611 | $28K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 789 | $26K |
| G0378 | Hospital observation service, per hour | <1% | 84 | $26K |
| 76830 | Ultrasound, transvaginal | <1% | 370 | $22K |
| A0425 | Ground mileage, per statute mile | <1% | 256 | $22K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,006 | $20K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,370 | $19K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,680 | $18K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,127 | $17K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 743 | $17K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,676 | $16K |
| 73030 | <1% | 927 | $16K | |
| 20610 | <1% | 480 | $15K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 76 | $15K |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 765 | $15K |
| 82607 | <1% | 2,140 | $15K | |
| 73130 | <1% | 999 | $15K | |
| 97162 | <1% | 297 | $15K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 62 | $14K |
| 84439 | <1% | 3,222 | $14K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 61 | $13K |
| 73630 | <1% | 979 | $12K | |
| 86900 | <1% | 481 | $12K | |
| 83970 | <1% | 625 | $12K | |
| 73610 | <1% | 767 | $11K | |
| 73110 | <1% | 597 | $11K | |
| 17110 | <1% | 179 | $11K | |
| 82728 | <1% | 1,635 | $10K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 749 | $10K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 965 | $9K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 697 | $8K |
| 97161 | <1% | 200 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,976 | $8K |
| 72100 | <1% | 307 | $7K | |
| 84481 | <1% | 853 | $7K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $6K |
| 85027 | <1% | 2,414 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,207 | $6K |
| 86376 | <1% | 821 | $6K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 399 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 54 | $6K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 214 | $6K |
| 83550 | <1% | 1,380 | $6K | |
| 87480 | <1% | 336 | $6K | |
| 87510 | <1% | 336 | $6K | |
| 87660 | <1% | 336 | $6K | |
| 73562 | <1% | 371 | $5K | |
| 83540 | <1% | 1,722 | $5K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,100 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 218 | $5K |
| 87186 | <1% | 1,656 | $5K | |
| 74018 | <1% | 244 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,460 | $5K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 493 | $5K |
| 82570 | <1% | 1,796 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 392 | $4K |
| 84403 | <1% | 322 | $4K | |
| 82043 | <1% | 1,353 | $4K | |
| 81001 | <1% | 9,834 | $4K | |
| 11100 | <1% | 64 | $3K | |
| 83880 | <1% | 910 | $3K | |
| 80305 | <1% | 2,440 | $3K | |
| 86038 | <1% | 595 | $3K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 55 | $3K |
| 85610 | <1% | 2,232 | $3K | |
| 83735 | <1% | 4,319 | $3K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 611 | $3K |
| 87077 | <1% | 830 | $3K | |
| 86140 | <1% | 1,442 | $2K | |
| 73564 | <1% | 57 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 589 | $2K |
| 81002 | <1% | 1,080 | $2K | |
| 87088 | <1% | 1,137 | $2K | |
| 99460 | <1% | 39 | $2K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | <1% | 125 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 823 | $2K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 24 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 65 | $2K |
| 87070 | <1% | 706 | $2K | |
| 94060 | <1% | 28 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 82 | $2K |
| 85652 | <1% | 1,527 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 162 | $1K |
| 83690 | <1% | 3,726 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 13 | $1K |
| 94726 | <1% | 26 | $1K | |
| 73502 | <1% | 88 | $1K | |
| 81025 | <1% | 4,400 | $1K | |
| 84402 | <1% | 97 | $1K | |
| 11102 | <1% | 24 | $1K | |
| 84702 | <1% | 257 | $1K | |
| 86780 | <1% | 159 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 344 | $1K |
| 87631 | <1% | 126 | $1K | |
| 84100 | <1% | 2,625 | $937.61 | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 15 | $851.19 |
| 72072 | <1% | 24 | $838.61 | |
| 74019 | <1% | 135 | $818.34 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 73 | $769.84 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 18 | $697.12 |
| 87075 | <1% | 366 | $647.18 | |
| 84153 | <1% | 63 | $597.52 | |
| 83655 | <1% | 69 | $596.48 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 65 | $576.71 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 44 | $574.66 |
| 87040 | <1% | 237 | $568.03 | |
| 87205 | <1% | 435 | $498.16 | |
| 86803 | <1% | 66 | $479.44 | |
| 83001 | <1% | 40 | $381.03 | |
| 84146 | <1% | 33 | $303.81 | |
| 85730 | <1% | 455 | $298.53 | |
| 82670 | <1% | 20 | $263.40 | |
| 86812 | <1% | 19 | $239.88 | |
| 73140 | <1% | 25 | $237.26 | |
| 90686 | <1% | 42 | $234.96 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 13 | $227.12 |
| 86200 | <1% | 34 | $213.09 | |
| 84484 | <1% | 2,703 | $204.86 | |
| 90715 | <1% | 30 | $194.04 | |
| 73560 | <1% | 14 | $192.56 | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $190.03 |
| 85379 | <1% | 468 | $189.12 | |
| 83002 | <1% | 18 | $186.24 | |
| 86431 | <1% | 69 | $184.36 | |
| 87340 | <1% | 71 | $176.74 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,035 | $164.53 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 30 | $160.43 |
| 86618 | <1% | 18 | $131.15 | |
| 86850 | <1% | 225 | $111.69 | |
| 83605 | <1% | 1,734 | $111.07 | |
| 82805 | <1% | 187 | $89.17 | |
| 86706 | <1% | 26 | $87.75 | |
| 86901 | <1% | 485 | $84.48 | |
| 83525 | <1% | 16 | $83.97 | |
| 72040 | <1% | 13 | $83.58 | |
| 94729 | <1% | 40 | $72.92 | |
| 82565 | <1% | 79 | $72.76 | |
| 82150 | <1% | 13 | $46.88 | |
| 86060 | <1% | 13 | $39.14 | |
| 82248 | <1% | 13 | $37.20 | |
| 80076 | <1% | 12 | $21.93 | |
| 82077 | <1% | 995 | $21.43 | |
| 84480 | <1% | 12 | $16.60 | |
| 94664 | <1% | 87 | $15.32 | |
| 87210 | <1% | 12 | $14.80 | |
| 82375 | <1% | 189 | $13.95 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,787 | $12.63 |
| 83050 | <1% | 188 | $9.29 | |
| 84436 | <1% | 12 | $8.04 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,704 | $7.46 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,685 | $5.33 |
| 84520 | <1% | 14 | $4.96 | |
| 84703 | <1% | 15 | $4.11 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,991 | $3.71 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,448 | $2.76 |
| 3074F | <1% | 65 | $0.16 | |
| 3078F | <1% | 33 | $0.08 | |
| 36416 | <1% | 1,916 | $0.01 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 649 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 3,218 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 500 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 14 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,290 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 170 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 65 | $0.00 |
| 96376 | 0% | 508 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 41 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 76 | $0.00 |
| 1101F | 0% | 82 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 14 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 43 | $0.00 |
| A9270 | Non-covered item or service | 0% | 60 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 12 | $0.00 |
| 94760 | 0% | 14 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 12 | $0.00 |
| 80050 | General health panel | 0% | 32 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 974 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,097 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 328 | $0.00 |
| 80179 | 0% | 316 | $0.00 | |
| 3288F | 0% | 82 | $0.00 | |
| 80143 | 0% | 355 | $0.00 | |
| 73590 | 0% | 12 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 12 | $0.00 |
| 90461 | 0% | 16 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 12 | $0.00 |
| 93017 | 0% | 12 | $0.00 | |
| 87634 | 0% | 26 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 46 | $0.00 |
| 99051 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKORTH-WHITE, KIRSTEN (PRESIDENT/CEO SOUTH REGION)
| Provider | Location | Paid |
|---|---|---|
| Munson Healthcare Grayling | Grayling, MI | $13.93M |
| Munson Healthcare Charlevoix Hospital | Charlevoix, MI | $8.26M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.